Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.03 | N/A | -250.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.03 | N/A | -250.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concerns about the recent performance but remains committed to long-term growth strategies. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the unexpected EPS loss and emphasized their focus on future projects.
They highlighted ongoing investments in research and development despite current challenges.
Ligand Pharmaceuticals reported a loss in EPS, which was significantly below expectations, indicating challenges in the current business environment. However, the stock rose by 2.15%, suggesting that investors may be optimistic about the company's long-term strategies and potential future growth. The lack of revenue details and guidance may leave some investors cautious, but the stock's positive reaction indicates some confidence in management's approach.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TEXAS PACIFIC LAND C
Apr 30, 2012